Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents

Journal of Medical Virology

Volumn 83, Issue 4, 2011, Pages 602-607

  Cheng, Pin Nan ^a   Liu, Wen Chun ^b   Tsai, Hung Wen ^a   Wu, I Chin ^a   Chang, Ting Tsung ^a   Young, Kung Chia ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b MINGDAO UNIVERSITY   (Taiwan)

Author keywords

Adefovir dipivoxil; Entecavir; Hepatitis B virus; Virus titer

Indexed keywords

ADEFOVIR DIPIVOXIL; CIRCULAR DNA; COVALENTLY CLOSED CIRCULAR DNA; ENTECAVIR; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER EXAMINATION; LIVER FIBROSIS; LIVER HISTOLOGY; MALE; TREATMENT OUTCOME;

ADENINE; ADULT; ANTIVIRAL AGENTS; BLOOD; DNA, CIRCULAR; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HISTOCYTOCHEMISTRY; HUMANS; LIVER; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PLACEBOS; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS B VIRUS;

EID: 79951528111     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22014     Document Type: Article

References (31)

1. Beck J, Nassal M. 2007. Hepatitis B virus replication. World J Gastroenterol 13: 48-64.
2. Biermer M, Puro R, Schneider RJ. 2003. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid integrity through activation of NF-κB. J Virol 77: 4033-4042.
3. Bohne F, Chmielewski M, Ebert G, Wiegmann K, Kurschner T, Schulze A, Urban S, Kronke M, Abken H, Protzer U. 2008. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 134: 239-247.
4. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D, Group BEAS. 2006. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001-1010.
5. Chen M, Sallberg M, Thung SN, Hughes J, Jones J, Milich DR. 2000. Nondeletional T-cell receptor transgenic mice: Model for the CD4(+) T-cell repertoire in chronic hepatitis B virus infection. J Virol 74: 7587-7599.
6. Chua PK, Wang RY, Lin MH, Masuda T, Suk FM, Shih C. 2005. Reduced secretion of virions and hepatitis B virus (HBV) surface antigen of a naturally occurring HBV variant correlates with the accumulation of the small S envelope protein in the endoplasmic reticulum and golgi apparatus. J Virol 79: 13483-13496.
7. Ganem D, Prince AM. 2004. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 350: 1118-1129.
8. Guo H, Jiang D, Zhou T, Cuconati A, Block TM, Guo JT. 2007. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: An intermediate of covalently closed circular DNA formation. J Virol 81: 12472-12484.
9. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, Adefovir Dipivoxil 438 Study G. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348: 800-807.
10. Huang CF, Lin SS, Ho YC, Chen FL, Yang CC. 2006. The immune response induced by hepatitis B virus principal antigens. Cell Mol Immunol 3: 97-106.
11. Ishak KG. 1994. Chronic hepatitis: Morphology and nomenclature. Mod Pathol 7: 690-713.
12. Khokhar A, Afdhal NH. 2008. Therapeutic strategies for chronic hepatitis B virus infection in 2008. Am J Med 121: S33-S44.
13. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. 1981. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1: 431-435.
14. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339: 61-68.
15. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L, Group BEAS. 2006. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354: 1011-1020.
16. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA, Globe Study G. 2007. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357: 2576-2588.
17. Lee WM. 1997. Hepatitis B virus infection. N Engl J Med 337: 1733-1745.
18. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. 2009. Control of cccDNA function in hepatitis B virus infection. J Hepatol 51: 581-592.
19. Liu WC, Lindh M, Buti M, Phiet PH, Mizokami M, Li HH, Sun KT, Young KC, Cheng PN, Wu IC, Chang TT. 2008. Genotyping of hepatitis B virus-genotypes a to g by multiplex polymerase chain reaction. Intervirology 51: 247-252.
20. Lu L, Ye D, Wang Y, Kwok A, Wong A, Yueng Y, Zhang H, Chen Y, Bowden S, Batrla-Utermann R, Locarnini S, Lau GK. 2008. Correlation between HBV cccDNA and HBsAg levels and their reduction by peginterferon alfa-2a based therapy in patients with chronic hepatitis B. Hepatology 48: 746A (979).
21. Lutgehetmann M, Volzt T, Quaas A, Zankel M, Fischer C, Dandri M, Petersen J. 2008. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 13: 57-66.
22. Manesis EK, Papatheodoridis GV, Hadziyannis E, Nastos T. 2008. HBsAg serum levels correlate with total liver HBV DNA but not with cccDNA. Hepatology 48: 371A (147).
23. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, Adefovir Dipivoxil 437 Study G. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348: 808-816.
24. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. 2008. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359: 2442-2455.
25. Minami M, Poussin K, Brechot C, Paterlini P. 1995. A novel PCR technique using Alu-specific primers to identify unknown flanking sequences from the human genome. Genomics 29: 403-408.
26. Seeger C, Mason WS. 2000. Hepatitis B virus biology. Microbiol Mol Biol Rev 64: 51-68.
27. Takehara T, Suzuki T, Ohkawa K, Hosui A, Jinushi M, Miyagi T, Tatsumi T, Kanazawa Y, Hayashi N. 2006. Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication. J Hepatol 44: 267-274.
28. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WEt, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. 2004. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126: 1750-1758.
29. Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. 2006. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 11: 909-916.
30. Wu TT, Coates L, Aldrich CE, Summers J, Mason WS. 1990. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 175: 255-261.
31. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J. 2006. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44: 675-684.